| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1039135375 |
| P356 | DOI | 10.1007/S00262-008-0648-5 |
| P932 | PMC publication ID | 2907477 |
| P698 | PubMed publication ID | 19156413 |
| P5875 | ResearchGate publication ID | 23804246 |
| P50 | author | Adam Giermasz | Q114575361 |
| P2093 | author name string | William Gooding | |
| Pawel Kalinski | |||
| Julie A Urban | |||
| Yutaro Nakamura | |||
| Payal Watchmaker | |||
| Rachel L Cumberland | |||
| P2860 | cites work | Regulation of interleukin-12 expression in human monocytes: selective priming by interferon-gamma of lipopolysaccharide-inducible p35 and p40 genes | Q24317746 |
| Dendritic cells and the control of immunity | Q27860918 | ||
| Identification and expression of mouse Langerin (CD207) in dendritic cells | Q28507435 | ||
| Interleukin-12 and the regulation of innate resistance and adaptive immunity | Q29614602 | ||
| T-cell priming by type-1 and type-2 polarized dendritic cells: the concept of a third signal | Q33774232 | ||
| Memory CD8+ T cells protect dendritic cells from CTL killing | Q34000039 | ||
| Helper function of memory CD8+ T cells: heterologous CD8+ T cells support the induction of therapeutic cancer immunity | Q34000201 | ||
| Complementary dendritic cell-activating function of CD8+ and CD4+ T cells: helper role of CD8+ T cells in the development of T helper type 1 responses. | Q34114993 | ||
| Perforin-dependent elimination of dendritic cells regulates the expansion of antigen-specific CD8+ T cells in vivo | Q34248293 | ||
| Dendritic cells as therapeutic vaccines against cancer | Q36085614 | ||
| Identification of proliferating dendritic cell precursors in mouse blood | Q36231236 | ||
| Induction of interferon gamma production by natural killer cell stimulatory factor: characterization of the responder cells and synergy with other inducers | Q36361001 | ||
| Dendritic cell progenitors phagocytose particulates, including bacillus Calmette-Guerin organisms, and sensitize mice to mycobacterial antigens in vivo | Q36362128 | ||
| Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines | Q36366108 | ||
| Interleukin (IL)-4 is a major regulatory cytokine governing bioactive IL-12 production by mouse and human dendritic cells | Q36368860 | ||
| Regulation of dendritic cell migration to the draining lymph node: impact on T lymphocyte traffic and priming | Q36371607 | ||
| Gene therapy of cancer based on interleukin 12. | Q36386455 | ||
| IL-18-induced CD83+CCR7+ NK helper cells | Q36403560 | ||
| Helper roles of NK and CD8+ T cells in the induction of tumor immunity. Polarized dendritic cells as cancer vaccines | Q36751608 | ||
| Enhanced activation of human dendritic cells by inducible CD40 and Toll-like receptor-4 ligation | Q40059146 | ||
| Tumor cell loaded type-1 polarized dendritic cells induce Th1-mediated tumor immunity | Q40355233 | ||
| Lymphocyte responses and cytokines | Q40620203 | ||
| Cytokine gene therapy of cancer using interleukin-12: murine and clinical trials. | Q41261328 | ||
| Dendritic cells mediate NK cell help for Th1 and CTL responses: two-signal requirement for the induction of NK cell helper function | Q43442797 | ||
| A novel bulk-culture method for generating mature dendritic cells from mouse bone marrow cells. | Q43975812 | ||
| Generation of human type 1- and type 2-polarized dendritic cells from peripheral blood | Q44269401 | ||
| Gene therapy of cancer with interleukin-12. | Q45863805 | ||
| Final maturation of dendritic cells is associated with impaired responsiveness to IFN-gamma and to bacterial IL-12 inducers: decreased ability of mature dendritic cells to produce IL-12 during the interaction with Th cells | Q54102042 | ||
| Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state | Q57779701 | ||
| CD8+ T Cell-Dependent Elimination of Dendritic Cells In Vivo Limits the Induction of Antitumor Immunity | Q62230837 | ||
| IL-4 Is a Mediator of IL-12p70 Induction by Human Th2 Cells: Reversal of Polarized Th2 Phenotype by Dendritic Cells | Q62589132 | ||
| Improved efficacy of dendritic cell vaccines and successful immunization with tumor antigen peptide-pulsed peripheral blood mononuclear cells by coadministration of recombinant murine interleukin-12 | Q63280965 | ||
| Granulocyte/macrophage-colony stimulating factor and interleukin-4 expand and activate type-1 dendritic cells (DC1) when administered in vivo to cancer patients. | Q64882566 | ||
| Susceptibility to Leishmania major infection in interleukin-4-deficient mice | Q70960225 | ||
| IL-12-engineered dendritic cells serve as effective tumor vaccine adjuvants in vivo | Q71871168 | ||
| Kinetics of dendritic cell activation: impact on priming of TH1, TH2 and nonpolarized T cells | Q73035410 | ||
| Development of Th1-inducing capacity in myeloid dendritic cells requires environmental instruction | Q73709048 | ||
| The role of interleukin-2, interleukin-12, and dendritic cells in cancer therapy | Q74148202 | ||
| IL-4 instructs TH1 responses and resistance to Leishmania major in susceptible BALB/c mice | Q74619595 | ||
| Dendritic cells require maturation via CD40 to generate protective antitumor immunity | Q77186016 | ||
| Polarized type-1 dendritic cells (DC1) producing high levels of IL-12 family members rescue patient TH1-type antimelanoma CD4+ T cell responses in vitro | Q79467943 | ||
| alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity | Q80516665 | ||
| P433 | issue | 8 | |
| P921 | main subject | dendritic cell | Q506253 |
| P304 | page(s) | 1329-1336 | |
| P577 | publication date | 2009-01-21 | |
| P1433 | published in | Cancer Immunology, Immunotherapy | Q5031409 |
| P1476 | title | Type-1 polarized dendritic cells primed for high IL-12 production show enhanced activity as cancer vaccines | |
| P478 | volume | 58 |
| Q41092396 | A phase I clinical study of autologous dendritic cell therapy in patients with relapsed or refractory multiple myeloma. |
| Q35865581 | Cellular immunotherapy using dendritic cells against multiple myeloma |
| Q34757261 | Chemokine expression from oncolytic vaccinia virus enhances vaccine therapies of cancer. |
| Q55457224 | Cross-talk between T Cells and Hematopoietic Stem Cells during Adoptive Cellular Therapy for Malignant Glioma. |
| Q34018782 | Cytotoxic T lymphocytes simultaneously targeting multiple tumor-associated antigens to treat EBV negative lymphoma |
| Q36256389 | DNA is an efficient booster of dendritic cell-based vaccine |
| Q37758502 | Dendritic cell subsets as vectors and targets for improved cancer therapy |
| Q42872791 | Dendritic cell vaccine in addition to FOLFIRI regimen improve antitumor effects through the inhibition of immunosuppressive cells in murine colorectal cancer model |
| Q37448957 | Dendritic cell-based therapeutic cancer vaccines: what we have and what we need |
| Q37821074 | Dendritic cells and immunity against cancer. |
| Q34649397 | Dendritic cells in cancer immunotherapy: vaccines and combination immunotherapies. |
| Q37778692 | Dendritic cells: are they clinically relevant? |
| Q35146556 | Designing the optimal vaccine: the importance of cytokines and dendritic cells. |
| Q42556531 | Enhancement of CTLs induced by DCs loaded with ubiquitinated hepatitis B virus core antigen |
| Q83513978 | Enhancement of protective immunity against intracellular bacteria using type-1 polarized dendritic cell (DC) vaccine |
| Q39256866 | G1-4 A, an arabinogalactan polysaccharide from Tinospora cordifolia increases dendritic cell immunogenicity in a murine lymphoma model |
| Q57158449 | Human Dendritic Cell Subsets |
| Q39658563 | IFNγ Markedly Cooperates with Intratumoral Dendritic Cell Vaccine in Dog Tumor Models |
| Q35156105 | IRAK-M removal counteracts dendritic cell vaccine deficits in migration and longevity |
| Q37527861 | Immunobiology of human mucin 1 in a preclinical ovarian tumor model |
| Q34216061 | Low molecular weight hyaluronan-pulsed human dendritic cells showed increased migration capacity and induced resistance to tumor chemoattraction. |
| Q37225501 | Modulation of chemokines in the tumor microenvironment enhances oncolytic virotherapy for colorectal cancer |
| Q34916497 | Monocyte-derived DC maturation strategies and related pathways: a transcriptional view |
| Q39390511 | NOD/scid IL-2Rgnull mice: a preclinical model system to evaluate human dendritic cell-based vaccine strategies in vivo |
| Q39200561 | Nanoparticle mediated co-delivery of paclitaxel and a TLR-4 agonist results in tumor regression and enhanced immune response in the tumor microenvironment of a mouse model |
| Q38031222 | Optimizing dendritic cell-based immunotherapy: tackling the complexity of different arms of the immune system |
| Q45344940 | Oral administration of soluble β‐glucans extracted from Grifola frondosa induces systemic antitumor immune response and decreases immunosuppression in tumor‐bearing mice |
| Q90522903 | Overexpression of Murine Rnaset2 in a Colon Syngeneic Mouse Carcinoma Model Leads to Rebalance of Intra-Tumor M1/M2 Macrophage Ratio, Activation of T Cells, Delayed Tumor Growth, and Rejection |
| Q38047054 | Phenotypic Plasticity of MDSC in Cancers |
| Q37735454 | Polarized dendritic cells as cancer vaccines: directing effector-type T cells to tumors |
| Q39520906 | Poly(I:C)-induced tumour cell death leads to DC maturation and Th1 activation |
| Q48219588 | Promoting the accumulation of tumor-specific T cells in tumor tissues by dendritic cell vaccines and chemokine-modulating agents. |
| Q37830226 | Recent developments in cancer vaccines |
| Q83781873 | Successful cross-presentation of allogeneic myeloma cells by autologous alpha-type 1-polarized dendritic cells as an effective tumor antigen in myeloma patients with matched monoclonal immunoglobulins |
| Q92541327 | Targeting and Specific Activation of Antigen-Presenting Cells by Endogenous Antigen-Loaded Nanoparticles Elicits Tumor-Specific Immunity |
| Q37922585 | Therapeutic vaccines in renal cell carcinoma |
| Q53293393 | Trp-P-1, a carcinogenic heterocyclic amine, inhibits lipopolysaccharide-induced maturation and activation of human dendritic cells |
| Q35174485 | Tumor immunotherapy using adenovirus vaccines in combination with intratumoral doses of CpG ODN |
| Q37728235 | Type I and II interferons enhance dendritic cell maturation and migration capacity by regulating CD38 and CD74 that have synergistic effects with TLR agonists |
| Q36989720 | Update on vaccine development for renal cell cancer |
Search more.